GURU.Markets stock price, segment price, and overall market index valuation
The company's share price SELLAS Life Sciences
The shares of SELLAS, an oncology biotech company, reflect the potential of its immunotherapy platform. The price trajectory is highly speculative and depends on the results of clinical trials of its drug candidates, which investors are pinning high hopes on.
Share prices of companies in the market segment - Cancer cure
SELLAS Life Sciences is an oncology company developing peptide-based immunotherapies for the treatment of various cancers. We've categorized it as a "Cancer Treatment" company. The chart below shows how investors view this high-risk but promising biotech segment.
Broad Market Index - GURU.Markets
SELLAS Life Sciences is an oncology company developing peptide-based immunotherapies for the treatment of various types of cancer. As a component of the GURU.Markets index, it represents a high-risk but promising segment of biotech. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SLS - Daily change in the company's share price SELLAS Life Sciences
Shares of SELLAS, an oncology company, exhibit extreme volatility, as measured by change_co. This indicator reflects sensitivity to clinical trial results. This metric is a key component of the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Cancer cure
SELLAS Life Sciences Group, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with SLS's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
SELLAS Life Sciences is a biotech company working on cancer immunotherapy. Its shares are preoccupied with anticipation of clinical trial results and regulatory decisions. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization SELLAS Life Sciences
SELLAS Life Sciences' year-to-date performance is a story of developing immunotherapy for cancer treatment. Its 12-month market cap is entirely dependent on clinical trial data for its GPS vaccine. Successful results in maintenance therapy for acute myeloid leukemia could be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Cancer cure
SELLAS Life Sciences Group, Inc. is a late-stage biotech company developing immunotherapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this cutting-edge field of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
SELLAS is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cancer immunotherapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization SELLAS Life Sciences
SELLAS Life Sciences shares move to the rhythm of scientific breakthroughs. Monthly price fluctuations don't reflect sales, but rather investors' reactions to the publication of clinical trial data for their cancer treatments. Each trial stage, whether successful or unsuccessful, triggers sharp movements on the chart, which essentially serves as a map of expectations in the world of biotech.
Monthly dynamics of market capitalization of the market segment - Cancer cure
SELLAS Life Sciences is an oncology company developing immunotherapies to combat various types of cancer. Its future depends entirely on the success of clinical trials. The biotech sector dynamics shown in the chart are a general barometer of investor sentiment toward risky but potentially breakthrough scientific projects, of which SELLAS is one.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
SELLAS Life Sciences Group is a late-stage biopharmaceutical company developing immunotherapies for the treatment of various types of cancer. The company's future depends on the results of clinical trials and regulatory decisions. The broader market chart serves only as a backdrop to understand how its potential to develop new cancer treatments has impacted its volatile stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization SELLAS Life Sciences
SELLAS Life Sciences Group is an oncology company in late-stage clinical development, focused on cancer immunotherapy. Its weekly stock price is highly volatile, depending on news about the progress of key clinical trials and potential approval of its drugs.
Weekly dynamics of market capitalization of the market segment - Cancer cure
SELLAS Life Sciences is developing immunotherapy for cancer treatment. Like many biotech companies in the research stage, the company doesn't yet have stable revenue. Its shares are a bet on future success. The chart will show how much its performance depends on development news versus general trends in the pharmaceutical industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
SELLAS is a clinical-stage biotech company. Its shares rely on news about trials, not macroeconomics. The chart clearly demonstrates how the company's performance is disconnected from the stock market and follows its own scientific calendar.
Market capitalization of the company, segment and market as a whole
SLS - Market capitalization of the company SELLAS Life Sciences
SELLAS Life Sciences' market capitalization chart represents a clinical-stage biotech company focused on developing cancer immunotherapy. Its valuation is highly volatile and depends on the clinical trial results of its lead drug candidate. It represents a high-risk bet on a new approach to fighting cancer.
SLS - Share of the company's market capitalization SELLAS Life Sciences within the market segment - Cancer cure
SELLAS Life Sciences is a clinical-stage oncology company developing immunotherapies for various types of cancer. Its market share currently reflects only the potential of its lead candidates. Its market capitalization is a risky bet on the success of its clinical trials and the promise of new ways to fight cancer.
Market capitalization of the market segment - Cancer cure
The chart below shows the overall value of the biotech sector. SELLAS Life Sciences is a company at the forefront of immuno-oncology. Its research aims to "train" the immune system to attack cancer cells. The potential of this market is enormous, and SELLAS, like many others, is striving to make a breakthrough in it, which is what is attracting the attention of investors.
Market capitalization of all companies included in a broad market index - GURU.Markets
SELLAS Life Sciences is an oncology company developing immunotherapeutic vaccines to fight cancer. Its market capitalization reflects the hope of developing a new class of anti-cancer drugs. The chart below shows the economic weight of companies working in this field.
Book value capitalization of the company, segment and market as a whole
SLS - Book value capitalization of the company SELLAS Life Sciences
SELLAS Life Sciences' foundation is its intellectual property in immunotherapeutic drugs for cancer treatment, specifically the GPS vaccine. The book value represents capital for late-stage clinical trials. The chart tells the story of a biotech company at a critical juncture, where research success could radically alter its balance sheet.
SLS - Share of the company's book capitalization SELLAS Life Sciences within the market segment - Cancer cure
SELLAS Life Sciences develops cancer immunotherapy. The chart shows its share of actual R&D assets. These include its laboratories and clinical programs, which provide the foundation for developing vaccines targeting a wide range of tumors.
Market segment balance sheet capitalization - Cancer cure
SELLAS Life Sciences is a biotech company whose value lies in its development portfolio. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, which underscores its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
SELLAS Life Sciences is an oncology company developing immunotherapies to combat cancer. Its assets are its clinical development pipeline. A modest stake in BCap_All is a material resource the company is investing in the development of vaccines that can "train" the immune system to attack tumors.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - SELLAS Life Sciences
SELLAS Life Sciences is an oncology immunotherapy company. Its entire market capitalization is a premium to its cash flow. This premium represents investors' bet on the success of its cancer vaccine in late-stage clinical trials.
Market to book capitalization ratio in a market segment - Cancer cure
SELLAS Life Sciences is an oncology company developing cancer immunotherapy. Its value is based almost entirely on the potential of its lead drug. The chart shows the huge premium to book value that investors are paying for the hope of success in clinical trials.
Market to book capitalization ratio for the market as a whole
SELLAS Life Sciences is a biopharmaceutical company developing immunotherapy for cancer treatment. Its valuation depends almost entirely on the success of clinical trials. This chart demonstrates how market value in the biotech sector can be detached from book value, reflecting hopes for future treatments.
Debts of the company, segment and market as a whole
SLS - Company debts SELLAS Life Sciences
SELLAS Life Sciences, an oncology company developing cancer immunotherapy, is raising capital to finance its late-stage clinical trials. The debt burden reflects the high costs associated with conducting large-scale research necessary to secure regulatory approval and bring its flagship vaccine to market.
Market segment debts - Cancer cure
SELLAS Life Sciences is a clinical-stage biopharmaceutical company specializing in cancer immunotherapy. Developing cancer vaccines is a long and risky process, requiring hundreds of millions of dollars. This chart shows how the company finances its expensive clinical trials, relying on equity and partnerships.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio SELLAS Life Sciences
SELLAS Life Sciences is an oncology company developing cancer immunotherapy. Its success depends on the results of clinical trials, which require millions of dollars. This chart shows the company's reliance on debt to finance its operations. This is a key indicator of its financial risk and "margin of safety" before entering the market.
Market segment debt to market segment book capitalization - Cancer cure
SELLAS Life Sciences Group is an immuno-oncology company developing cancer vaccines. The chart shows debt trends in their sector. For a company in clinical trials, this allows them to assess how they finance their expensive research and how their financial model, dependent on the success of these trials, compares to other biotech startups.
Debt to book value of all companies in the market
SELLAS Life Sciences is an oncology company in the clinical development stage of cancer vaccines. Its survival and progress depend entirely on its ability to attract equity capital to fund expensive research. This chart, reflecting the debt burden in the economy, clearly demonstrates that SELLAS's financial model is a bet on the future, not on stable cash flow.
P/E of the company, segment and market as a whole
P/E - SELLAS Life Sciences
SELLAS Life Sciences Group is an oncology company developing immunotherapeutic drugs for the treatment of various types of cancer. This chart reflects investor expectations for its lead drug candidate. The valuation is entirely dependent on success in late-stage clinical trials and future commercial potential.
P/E of the market segment - Cancer cure
This industry chart for biotech companies provides key context for SELLAS Life Sciences. It reflects overall high valuations based on breakthrough hopes. Comparisons with this chart help understand whether the immunotherapeutic cancer vaccine being developed by SELLAS is considered more or less promising than those of dozens of other oncology biotechs.
P/E of the market as a whole
SELLAS Life Sciences is a clinical-stage oncology company developing immunotherapies to combat various types of cancer. Its valuation is entirely dependent on the results of future studies. This overall risk appetite curve in biotech is vital for SELLAS, as it determines whether the company will be able to raise capital to complete its clinical programs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company SELLAS Life Sciences
SELLAS Life Sciences is an oncology company in late-stage clinical development, focused on cancer immunotherapy. This chart shows investor expectations for its lead drug candidate. The valuation is highly dependent on the results of late-stage clinical trials and potential regulatory approval, which could dramatically change the company's future.
%20P%2FE%20SELLAS%20Life%20Sciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-SELLAS-Life-Sciences&v=1772558382701 "Chart of the company's future (projected) P/E SELLAS Life Sciences")
Future (projected) P/E of the market segment - Cancer cure
SELLAS Life Sciences is a biopharmaceutical company focused on developing immunotherapies for the treatment of various types of cancer. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess the market's perception of its lead drug and its potential for treating acute myeloid leukemia.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772558382706 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
SELLAS Life Sciences is a clinical-stage oncology company developing immunotherapies for the treatment of various types of cancer. For a biotech company like SELLAS, this market risk appetite curve is vital. Raising capital for late-stage clinical trials and potential commercialization directly depends on investors' confidence in their technology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772558382707 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit SELLAS Life Sciences
SELLAS Life Sciences is an oncology company developing immunotherapies for the treatment of various types of cancer. Its lead candidate targets a broad range of tumors. This chart shows the company's financial performance during the clinical trials phase, where it aims to prove the effectiveness of its approach.
Profit of companies in the market segment - Cancer cure
SELLAS Life Sciences is a biopharmaceutical company developing immunotherapies for cancer treatment. This chart shows profitability in the oncology sector. For SLS, this reflects the hopes surrounding their lead drug, which targets a broad range of tumors. The success of their clinical trials is key to the company's future.
Overall market profit
SELLAS Life Sciences is an oncology company developing a new class of immunotherapy (cancer vaccines) targeting a broad range of tumors. This is a promising direction, but carries high risks. The company's success depends entirely on the results of clinical trials. This overall market profitability chart does not reflect the potential of such scientific breakthroughs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company SELLAS Life Sciences
SELLAS Life Sciences is an oncology company developing immunotherapeutic drugs for the treatment of various types of cancer. The revenue projections presented here are speculative and depend on the success of its lead candidate, galinpepimut-C (GPS), in late-stage clinical trials, particularly for the treatment of acute myeloid leukemia.
%20profit%20of%20the%20company%20SELLAS%20Life%20Sciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-SELLAS-Life-Sciences&v=1772558382834 "Graph of future (projected) profit of the company SELLAS Life Sciences")
Future (predicted) profit of companies in the market segment - Cancer cure
SELLAS Life Sciences is an oncology company developing immunotherapies for a wide range of cancers. The revenue forecast for this segment depends on the results of late-stage clinical trials. This chart reflects the collective belief among analysts that new immunotherapy approaches will expand the range of patients who respond to treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772558382851 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
SELLAS Life Sciences is an oncology company in late-stage clinical development, focused on cancer immunotherapy. Its future depends almost entirely on the approval of its lead drug. The market revenue forecasts presented here influence investor sentiment and risk assessment in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772558382861 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - SELLAS Life Sciences
SELLAS Life Sciences is an oncology company developing immunotherapies for the treatment of various cancers. This chart shows a high speculative valuation. Investors are betting on its lead drug candidate and its potential for use in combination with other treatments, assessing future clinical success.
P/S market segment - Cancer cure
SELLAS Life Sciences is an oncology company developing immunotherapeutic drugs for the treatment of various types of cancer. Its lead candidate targets a broad range of tumors. This chart shows the average revenue estimate in the biotech sector, which helps understand investor expectations for SELLAS's clinical trials and potential success.
P/S of the market as a whole
SELLAS Life Sciences is an oncology company developing immunotherapeutic drugs for the treatment of various types of cancer. Its lead candidate is aimed at preventing relapses. The company's success depends entirely on the results of clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk biotech companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company SELLAS Life Sciences
SELLAS Life Sciences is an oncology company developing immunotherapy drugs for various types of cancer. This chart shows how the market values the company based on its future revenue potential. It reflects expectations for the success of its cancer vaccines in clinical trials.
%20P%2FS%20SELLAS%20Life%20Sciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-SELLAS-Life-Sciences&v=1772558382920 "The graph of the company's future (projected) P/S SELLAS Life Sciences")
Future (projected) P/S of the market segment - Cancer cure
SELLAS Life Sciences is an oncology company developing next-generation immunotherapies for the treatment of various cancer types. Its lead candidate targets a broad range of tumors. This chart reflects investors' confidence in its scientific platform and the potential of its drugs to become a universal treatment in the fight against cancer.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772558382931 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
SELLAS Life Sciences is a clinical-stage immuno-oncology company developing cancer vaccines. Their future depends entirely on the results of clinical trials and their ability to raise capital. This market optimism is vital for SLS. Financing such risky projects is only possible when investors are optimistic and willing to wait.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772558382943 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales SELLAS Life Sciences
SELLAS Life Sciences is a clinical-stage immuno-oncology company developing vaccines and targeted therapies for the treatment of various types of cancer. Currently, the company has no approved products on the market. This timeline will demonstrate its ability to commercialize its developments and offer patients new treatments for cancer.
Sales of companies in the market segment - Cancer cure
SELLAS Life Sciences is a late-stage clinical development biopharmaceutical company developing a new generation of immunotherapeutic agents for the treatment of a wide range of cancers. Their flagship drug is aimed at preventing relapses. Currently, the company does not yet generate commercial revenue from product sales.
Overall market sales
SELLAS Life Sciences is an oncology company developing immunotherapeutic drugs for the treatment of various types of cancer. Its lead candidate is aimed at preventing relapse after successful treatment. This total revenue chart includes the healthcare sector, where SLS is working to solve one of the most challenging problems in oncology: preventing disease recurrence.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company SELLAS Life Sciences
SELLAS Life Sciences is an oncology company developing immunotherapeutic vaccines for the treatment of various cancers, including acute myeloid leukemia and breast cancer. This chart reflects analysts' confidence in the potential of its lead drug candidate and its ability to improve patient outcomes.
%20sales%20of%20the%20company%20SELLAS%20Life%20Sciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-SELLAS-Life-Sciences&v=1772558382982 "Schedule of future (projected) sales of the company SELLAS Life Sciences")
Future (projected) sales of companies in the market segment - Cancer cure
SELLAS Life Sciences is an oncology company developing next-generation immunotherapies targeting a wide range of tumors. This chart shows forecasts for the entire immuno-oncology market. It illustrates expectations for the emergence of drugs that could be effective against various cancer types and work in combination with existing therapies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772558382994 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
SELLAS Life Sciences, an immuno-oncology company, sees this chart as a reflection of investment appetite for biotechnology. The stable economic growth projected here provides the capital needed to conduct late-stage clinical trials of cancer vaccines. This capital is vital for the commercialization of SELLAS's developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772558383017 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality SELLAS Life Sciences
SELLAS Life Sciences is an oncology company developing immunotherapies for various types of cancer. Currently in the clinical stage, it is focused on research. This chart shows not current profits, but rather the capital burn rate—a key metric for biotech companies, reflecting the amount of investment in developing future drugs.
Market segment marginality - Cancer cure
SELLAS Life Sciences is an oncology company developing immunotherapeutic drugs for the treatment of various types of cancer. This chart reflects the potential of its leading candidates. Future high operating income will confirm the clinical efficacy and commercial viability of its vaccines.
Market marginality as a whole
SELLAS Life Sciences is a clinical-stage immuno-oncology company developing cancer vaccines. Its value and future depend solely on the results of clinical trials. This gross profitability chart has absolutely no bearing on the world of biotech, where science and data are king.
Employees in the company, segment and market as a whole
Number of employees in the company SELLAS Life Sciences
SELLAS Life Sciences is a clinical-stage oncology company developing a new type of cancer immunotherapy—therapeutic vaccines. Its lead candidate targets a broad range of tumors. This graph shows a small team of scientists conducting clinical trials, hoping to create a universal treatment for cancer.
Share of the company's employees SELLAS Life Sciences within the market segment - Cancer cure
SELLAS Life Sciences is an oncology company developing immunotherapies for a wide range of cancers. Conducting numerous late-stage clinical trials requires a growing team of physicians, scientists, and regulatory affairs specialists. This chart demonstrates its potential and growing importance in cancer vaccine development.
Number of employees in the market segment - Cancer cure
SELLAS Life Sciences is an oncology company developing immunotherapeutic cancer vaccines. Its drugs are designed to "train" the patient's immune system to recognize and attack tumor cells. This graphic shows a team of immunologist scientists working on a new approach to cancer treatment that could prevent recurrence.
Number of employees in the market as a whole
SELLAS Life Sciences Group is an oncology company focused on developing cancer immunotherapy. Their work requires significant, long-term investment. The overall economic climate, as measured by employment trends, creates the conditions for such financing. The growing market is attracting capital to the biotech sector, allowing SELLAS to advance its clinical programs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company SELLAS Life Sciences (SLS)
SELLAS Life Sciences is an oncology company developing immunotherapy. This chart is a clear bet on science. Like many biotech companies without revenue, their per-employee market cap can be very high. This reflects not operational efficiency, but rather investors' faith that their drugs will pass trials and become a new standard of care.
%20of%20the%20company%20SELLAS%20Life%20Sciences%20(SLS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-SELLAS-Life-Sciences-SLS&v=1772558383237 "Chart of market capitalization per employee (in thousands of dollars) of the company SELLAS Life Sciences (SLS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
SELLAS Life Sciences is a biopharmaceutical company focused on developing immunotherapies for cancer treatment. Its market cap reflects investor expectations for clinical trials. This chart shows how the market values its scientific potential relative to its small but highly specialized staff compared to other oncology companies.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772558383261 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
SELLAS Life Sciences is an oncology company developing cancer immunotherapy. For a clinical-stage biotech, this metric reflects investor expectations. It shows how the market perceives the potential of its leading candidates, which, if successful, could become new treatment standards.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772558383355 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company SELLAS Life Sciences (SLS)
SELLAS is a clinical-stage biotech company developing immunotherapies (vaccines) against cancer. This graph is negative. The company has no product revenue. Its small staff of scientists is dedicated to conducting clinical trials. Each employee is an investment in technology that, if successful, could be worth billions.
%20Chart%20SELLAS%20Life%20Sciences%20(SLS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-SELLAS-Life-Sciences-SLS&v=1772558383371 "Company Profit Per Employee (in thousands of dollars) Chart SELLAS Life Sciences (SLS)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
SELLAS Life Sciences is an oncology company specializing in the development of immunotherapies (vaccines) targeting a wide range of cancers, specifically the WT1 protein. This chart represents an industry benchmark. For clinical-stage biotech companies, it serves as a benchmark, demonstrating the potential profitability the sector aspires to achieve if their vaccine candidates are successful.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772558383405 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
SELLAS Life Sciences is a clinical-stage biotech company focused on immuno-oncology. They develop vaccines (GPS) designed to "teach" the immune system to attack specific targets on cancer cells (for example, in AML). This is R&D. The chart shows the R&D investment (negative return) per scientist working on this technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772558383434 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee SELLAS Life Sciences (SLS)
SELLAS Life Sciences is an oncology company developing immunotherapies for various types of cancer. This graph reflects the clinical development stage. Future revenue growth per employee will be directly dependent on the success of its lead candidate, galinpepimut-S, in late-stage trials and its subsequent market launch.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-SELLAS-Life-Sciences-SLS&v=1772558383479 "Sales chart per company employee SELLAS Life Sciences (SLS)")
Sales per employee in the market segment - Cancer cure
SELLAS Life Sciences (SLS) is a clinical-stage biotech developing cancer immunotherapies (vaccines). They have no commercial revenue. This chart is typical for R&D companies: it compares their research staff working on future products with zero current revenue, which contrasts sharply with the sector average.
Sales per employee for the market as a whole
SELLAS Life Sciences is a biotech company focused on developing vaccines and immunotherapies for cancer (particularly breast cancer). It's a pure R&D operation. This graph likely shows zero revenue, as their research team is in advanced clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company SELLAS Life Sciences (SLS)
SELLAS Life Sciences (SLS) is a clinical-stage biotech developing cancer immunotherapies (vaccines) targeting the WT1 antigen. This chart shows bearish bets. The high short interest reflects investors' deep skepticism about their lead drug, which is currently undergoing trials, and the generally high risk of cancer vaccine development.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-SELLAS-Life-Sciences-SLS&v=1772558383571 "Short Shares Chart for the Company SELLAS Life Sciences (SLS)")
Shares shorted by market segment - Cancer cure
SELLAS Life Sciences (SLS) is an oncology company developing immunotherapies (vaccines) for the treatment of various cancers, including acute myeloid leukemia. This chart illustrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about the risks of clinical trials.
Shares shorted by the overall market
SELLAS Life Sciences is a clinical-stage oncology biotech. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing SLS will be unable to raise funds to continue R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator SELLAS Life Sciences (SLS)
SELLAS Life Sciences is a biotech company whose fate hinges on a single flagship cancer drug (Galinpepimut-S). It's a binary bet. This chart measures the extremes of speculative expectations. It shows when the stock is "overbought" on the euphoria of trial data or "oversold" to the bottom.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-SELLAS-Life-Sciences-SLS&v=1772558383645 "RSI 14 indicator chart for the company's stock SELLAS Life Sciences (SLS)")
RSI 14 Market Segment - Cancer cure
SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies (vaccines), specifically those targeting the WT1 protein. This chart reflects the overall sentiment in the oncology sector and helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
SELLAS Life Sciences (SLS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SLS (SELLAS Life Sciences)
SELLAS Life Sciences is a biopharmaceutical company developing immunotherapies (including the GPS "cancer vaccine") targeting the WT1 protein for the treatment of various cancers. This chart shows the speculative average price target from analysts, based on their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SLS-SELLAS-Life-Sciences&v=1772558383719 "A chart showing analyst consensus forecasts for the expected stock price. SLS (SELLAS Life Sciences)")
The difference between the consensus estimate and the actual stock price SLS (SELLAS Life Sciences)
SELLAS Life Sciences is a late-stage biotech company whose fate hinges on a single drug: Galinpepimut-S. It's a cancer "vaccine" designed to prevent relapse in patients with AML (leukemia). This chart reflects analysts' speculative expectations for the final data from their clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SLS-SELLAS-Life-Sciences&v=1772558383791 "A chart showing the difference between the consensus forecast and the actual stock price. SLS (SELLAS Life Sciences)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
SELLAS (SLS) is a biotech company developing immunotherapies (vaccines) that "train" a patient's immune system to recognize and attack cancerous tumors. This chart shows analysts' overall expectations for the cancer treatment sector. It reflects whether experts believe in a breakthrough in "cancer vaccines" or consider R&D too risky.
Analysts' consensus forecast for the overall market share price
SELLAS Life Sciences is a biotech company specializing in the development of cancer immunotherapies (vaccines) targeting a wide range of tumors. This chart shows the overall risk appetite. For SELLAS, a clinical-stage company whose value is based on future expectations, overall market optimism is critical for raising capital for research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index SELLAS Life Sciences
SELLAS is a clinical-stage biotech company focused on immuno-oncology. Their flagship product (GPS) is a cancer vaccine targeting the WT1 protein, which is designed to prevent cancer recurrence (e.g., AML). This graph is a clear indicator of faith in their R&D. Its dynamics depend entirely on their progress in clinical trials and their chances of FDA approval.
AKIMA Market Segment Index - Cancer cure
SELLAS Life Sciences is a clinical-stage biopharmaceutical company developing immunotherapies (vaccines) for the treatment of various types of cancer. This chart shows the average index for the cancer treatment sector. It provides investors with a benchmark for how SELLAS's scientific platform compares to the sector average among companies seeking breakthroughs in oncology.
The AKIM Index for the overall market
SELLAS Life Sciences is a biopharmaceutical company developing peptide immunotherapies for the treatment of various types of cancer (GPS). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to the overall economic trends affecting the oncology sector.
